This potential intravenous treatment was developed from a blood sample of a U.S. COVID-19 survivor after researchers identified an antibody that showed promise in fighting off the novel coronavirus. The drugmaker’s scientists copied the antibody to produce a therapy focused on blocking and neutralizing the coronavirus.
The drug’s first study will involve up to 32 COVID-19 patients and will mainly test safety and efficacy. Eli Lilly plans to additionally test if the antibody therapy can prevent COVID-19 in at-risk individuals. If so, it could be used as a preventive treatment while a vaccine is still being developed.
If testing goes well, the drugmaker plans to introduce a second study that will treat patients who are not hospitalized.
More articles on pharmacy:
6 BCBS companies sue CVS, claiming decadelong insurance fraud scheme
Georgia pharma company recalls thyroid drug for super potency
University of Arkansas researchers receive NIH grant for experimental heart drug
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
